Copenhagen, Denmark; December 5, 2006 – Genmab A/S (CSE: GEN) announced today that the company’s partner Roche has named the disease areas for the antibody programs developed with Genmab. These include inflammation, oncology, respiratory and vascular diseases. The antibodies are primarily at the pre-clinical stage with one in Phase I development. The development of one of the programs is carried out in collaboration with one of the world’s largest biotech companies, the American company Genentech, where Roche owns a majority stake.

This information was presented today at The European Antibody Congress 2006 (Lyon, France) in a joint presentation between Monique Huser, Global Alliance Director, Research and Technologies Roche and Genmab’s Chief Scientific Officer, Prof. Jan van de Winkel. The talks focused on building a successful collaboration in antibody development and sustaining a productive partnership.